Metrics as of 10/17/2026, 09:26 AM (Berlin time), refresh in progress.
Pasithea Therapeutics Stock
Pasithea Therapeutics Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Tiago Reis Marques
- Employees
- 5
- Market cap
- $14 M
- IPO
- 15/09/2021
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These…
Pasithea Therapeutics stock: price history
1D
+2.4%
1W
-10.2%
1M
-14.3%
6M
-43.4%
YTD
-67.4%
1Y
-42.5%
2Y
-89.4%
5Y
-99.3%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~35% stronger price swings than usual
Ask the agents about Pasithea Therapeutics
Analyst assessment of Pasithea Therapeutics
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 16/06/2026
Pasithea Therapeutics stock metrics
P/E
-0.17
P/B
0.06
EV/EBITDA
1.36
RETURN ON EQUITY
-10.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.4%
FLOAT SHARES
32,213,767
AVG. DAILY VOLUME (30D)
155,604
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Pasithea Therapeutics stock
What does Pasithea Therapeutics do?
Pasithea Therapeutics Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Tiago Reis Marques, the company employs around 5 people.
The IPO was on 15/09/2021; the stock trades on NASDAQ under the ticker KTTA.
What do analysts say about Pasithea Therapeutics stock?
2 analysts rate the stock, the consensus is Buy (as of 16/06/2026).
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Pasithea Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 35% stronger than usual.
Does Pasithea Therapeutics pay a dividend?
No, Pasithea Therapeutics currently does not pay a dividend.
Which stocks are comparable to Pasithea Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Pasithea Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Pasithea Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.